Taizhou Crene Biotechnology Co., Ltd.
                                                                                                           
Verified Supplier
19 Years
Since 2007
Menu
Chemicals Chemical Reagents

A66 Cas 1166227-08-2 PI3K Inhibitors P110 Inhibitor

Price Negotiable
Price: Negotiable
MOQ: Negotiable
Delivery Time: Negotiable
Product Description

+ AII PRODUCTS

- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others

Product

Size

Price

Stock

Quantity

Get Quotation Now Add to Cart Bulk Inquiry

 

A66 Cas 1166227-08-2 PI3K Inhibitors P110 Inhibitor

 

AddThis Sharing Buttons

Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

 

Chemical Information

Product name:A66

Purity:98% min

CAS NO:1166227-08-2

Solubility:DMSO50 mg/mL (127.06 mM)

Molecular Formula:C17H23N5O2S2

Package:Package according to customer requirements

Molecular Weight:393.527

Storage:Store at -20℃

 

Quality control

COA

Remarks

A66 is a potent and highly selective p110 inhibitor with IC50 of 32 nM in a cell-free assay, >100 fold selectivity for p110 over other class-I PI3K isoforms. A66 blocks phosphoinositide 3-kinase signalling and tumour growth in certain cell types.

 

Related Products:

Idelalisib; Almorexant HCL; IC-87114; Pictilisib; Pictilisib mesylate; XL147; PIK-90; Omipalisib; Buparlisib; TG100-115; A66; AS-252424; GSK2636771; CH5132799; 3-methyladenine; AS-604850

 

References

[1].Jamieson S, et al. A drug targeting only p110 can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J, 2011, 438(1), 53-62.

[2].Sun M, et al. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A, 2010, 107(35), 15547-15552.

Get in Touch

Have questions about our products or want to discuss a custom order? Our team is ready to help you.

Company Taizhou Crene Biotechnology Co., Ltd.
Location Add: Economic Developed Zone of Taizhou Zhejiang China.

Request A Quote

Please check your email address.
Your message must be at least 20 characters.